Akouos
PublicAkouos is now publicly traded
The data on this page reflects Akouos's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jun 30, 2020
Last Round
M&A
Oct 18, 2022
Est. Valuation at Exit
$610M
Total Funding Raised
$893.97M
Company Overview
Akouos (NAS: AKUS) is a biotechnology company specializing in gene therapies aimed at restoring, improving, and preserving hearing for individuals with inner ear disorders.
Sector
Biotech
AI Layer
Non-AI
Keywords
Akouos Comparables
Compare Akouos with similar companies based on industry and business-model similarity.
No public comparables are available for Akouos. Request access to learn about comparables coverage.
Request accessAkouos Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Oct 18, 2022 | ||||
| IPO | Jun 30, 2020 | ||||
| Series B | Feb 27, 2020 | ||||
| Series A | Aug 7, 2018 | ||||
| Seed | Nov 30, 2017 |
Akouos Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B |
| RA Capital Management | Series A, Series B |
| New Enterprise Associates (NEA) | Series B, Seed, Series A |
| Mass General Brigham Innovation | Seed, Series A, Series B |
| Fidelity Management & Research Company | Series B |
| TD Securities | Series B |
| Blue Owl Capital | Series B |
Akouos Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access